BioMarin Pharmaceutical Signs an Agreement with Deep Genomics on Advancing Programs Identified Using Artificial Intelligence

 BioMarin Pharmaceutical Signs an Agreement with Deep Genomics on Advancing Programs Identified Using Artificial Intelligence

BioMarin Pharmaceutical Signs an Agreement with Deep Genomics on Advancing Programs Identified Using Artificial Intelligence

Shots:

  • Deep Genomics will receive an undisclosed upfront payment and is eligible to receive development milestones, BioMarin will receive an exclusive option to obtain Deep Genomics’ rights to each program for development & commercialization
  • Deep Genomics will use its AI drug discovery platform (The AI workbench) to identify & validate target mechanisms, lead candidates & BioMarin will advance them into preclinical & clinical development
  • AI workbench enables rapid exploration of novel targetable mechanisms & therapeutic candidates, it combines deep learning, automation, advanced biomedical knowledge & massive amounts of in vitro & in vivo data to accurately identify targetable molecular mechanisms & guide the discovery & development of oligonucleotide therapies

Click here ­to­ read full press release/ article | Ref: BioMarin | Image: BioMarin

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post